Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-2: Phase III trial of iclepertin for cognitive impairment associated with schizophrenia
jRCT2031210241Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iclepertin arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in MCCB overall composite T-score at 26 weeks. Started Aug 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2031210241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210241.